Neurodyn_slider_Web_Horiz
Neurodyn utilizes a portfolio approach to identify, validate, and develop bioactives for neuroprotection and the early treatment of neurological diseases. Neurodyn identifies bioactive compounds within historically-proven natural treatments with the goal of validating therapeutic candidates and ultimately developing treatments for Parkinson’s, Alzheimer’s, ALS and chronic nerve pain. Neurodyn will out-license or sell validated therapeutic candidates to pharmaceutical and consumer health players, as well as explore faster alternatives to traditional drug development, such as the US FDA Medical Food designation.

Neurodyn’s unique insight into the discovery, validation, and development of new bioactive compounds comes from a strong development capacity based on international partners with demonstrated historical knowledge of natural compounds, in-house medicinal chemistry capability, and proprietary animal models of neurological disease.

News

NeuroQuest Inc. announces synthetic chemistry services

(November 12, 2014 | Halifax)  Neurodyn Life Sciences Inc....

Positive Phase 1a outcome for Memogain® means potential new treatment for Alzheimer’s disease

(September 9, 2014 – Charlottetown, Prince Edward...

Neurodyn Inc. creates Memogain® Advisory Board

(February 21, 2014) Neurodyn Inc. commenced a Phase 1A...

Read More